Pamiparib
帕米帕利PARP inhibitor not renewed in the 2026 NRDL adjustment; explicitly granted a 6-month transition period under original payment terms through June 30, 2027.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字H20210016
- Initial Approval Date
- May 7, 2021
- Notice Published
- May 7, 2021
- MAH
- BeiGene (Suzhou) Co., Ltd. (百济神州(苏州)生物科技有限公司)
- Approved Scope
- Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Adjustment
- Removed from 2026 NRDL (non-renewed negotiated drug)
- Transition Clause
- Original payment standard continues through Jun 30, 2027
- Prior 2025 Listing
- 2025 NRDL #256 (Class B) — Restricted to patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after ≥2 prior lines of chemotherapy.
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字H20210016 | Capsule (胶囊剂) 20mg | Initial Approval Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy. 附条件批准用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。 | Approved: 2021-05-07 Published: 2021-05-07 | BeiGene (Suzhou) Co., Ltd. |
Change Timeline
- (2027-06-30)Transition Clause· Notice published: Nov 14, 2026
6-Month Transition Period Ends
Original negotiated payment standard remains reimbursable through June 30, 2027 per the 2026 NHSA notice.
Chinese original: 未成功续约调出谈判药品给予6个月过渡期,2027年6月底前医保基金可按原支付标准继续支付。
NHSA · Section I(1) Transition ClauseVerified 2026-11-20 - (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Removed from Negotiated List
Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.
Chinese original: 未成功续约调出2026版目录(原2025版谈判第256项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。
NHSA · Section I(1) Transition ClauseVerified 2026-11-20 - (2021-05-07)NMPA Approval
NMPA Initial Marketing Approval (国药准字H20210016 · 20mg)
Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy.
Chinese original: 附条件批准用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。
NMPA · NMPA Registration H20210016Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NHSAPublished 2026-11-14国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》(2026年)的通知Retrieved 2026-11-20
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20